Unlocking the Potential of Undruggable Targets in Drug Discovery
In the ever-evolving landscape of drug discovery, a new horizon has emerged: transforming the "undruggable" into viable targets for therapeutic intervention. At Promega, we provide cutting-edge tools and insights that empower researchers across the industry. Our focus is on turning the challenges of yesterday into the breakthroughs of tomorrow, particularly in areas once thought insurmountable.
We are proud to spotlight innovative solutions in key areas of drug discovery:
- RAS Biology: Unraveling the complexities of one of the most notorious targets in cancer research.
- Induced Proximity: Harnessing molecular machineries to selectively degrade or modify proteins of interest.
- Protein-Protein Interactions: Offering tools to dissect and target these intricate networks, critical for numerous cellular processes.
- Targeting RNA: Exploring the vast potential of RNA as a therapeutic target with novel approaches.
At Promega, we are not just a solutions provider; we are your partner in the journey to illuminate the path forward in drug discovery. Together, we can tackle the once "undruggable" with innovative technologies and collaborative spirit.
Register for on-demand access to our Undruggables Virtual Event, in which leaders in the field present innovative approaches for tackling undruggable targets.
Overview
Historically, the undruggable category encompassed proteins and molecules with flat surfaces, lacking the grooves or pockets where small molecules could bind, making them challenging for drug interaction. Additionally, the complexity of protein-protein interactions and the dynamic nature of RNA have posed significant hurdles.
Recent advances, however, are changing the landscape. Innovative techniques such as induced proximity, which brings molecules together to effect a change, and novel approaches targeting RNA, are providing fresh avenues for intervention. In parallel, advancements in understanding RAS biology have opened doors to targeting what was once considered the epitome of undruggability.
Looking forward, the trajectory of drug discovery is set towards expanding the druggable universe. Through a combination of cutting-edge research, technological innovation, and collaborative efforts, we are beginning to see a future where no target is beyond reach. This shift not only promises new therapies for patients but also underscores the importance of continuous exploration and adaptation in the field.
RAS Biology
RAS proteins, pivotal in cell signaling pathways, have long stood as symbols of the "undruggable" targets in cancer research. Their role in driving numerous cancers when mutated makes them attractive targets for therapeutic intervention. However, the inherent structural features of RAS proteins have historically rendered them resistant to the small molecule and antibody-based therapies.
Despite these challenges, the landscape of RAS targeting is rapidly evolving. Recent breakthroughs have unveiled new strategies for inhibiting RAS activity, offering hope for developing effective cancer therapies. At Promega, we are committed to propelling this momentum forward. Our comprehensive suite of tools for RAS research is designed to support the discovery and development of novel inhibitors that can outmaneuver the complexities of RAS biology. Explore our RAS Tools.
Induced Proximity: The Future of Molecular Intervention
In the quest to expand the boundaries of drug discovery, the concept of induced proximity emerges as a transformative approach. This innovative strategy leverages the principle of bringing two proteins close together to modulate disease-causing pathways. By harnessing the power of induced proximity, researchers can now target proteins that were once considered undruggable due to their lack of conventional binding sites or their pivotal roles in cellular functions.
Promega is at the forefront of this exciting field, offering a suite of tools designed to enable the discovery and development of therapies based on induced proximity. Our technologies facilitate the study of protein-protein interactions, permeability, and degradation, providing a comprehensive platform for unlocking new therapeutic potentials.
Explore our applications in protein degradation drug discovery and take a step towards overcoming the challenges of the undruggable.
Read our Blog about how to use Structural Computation Models to Predict Productive PROTAC Ternary Complexes.
Deciphering Protein-Protein Interactions: Tools for the Intractable
Protein-protein interactions (PPIs) are fundamental to virtually all biological processes, making them critical targets for therapeutic intervention. However, their dynamic and complex nature has traditionally placed them in the realm of "undruggable" targets. The transient and often weak interactions between proteins, coupled with large, flat interaction surfaces, challenge conventional drug discovery methods.
Recognizing the untapped potential in modulating PPIs for disease treatment, Promega has developed a range of innovative technologies specifically designed to study and target these intricate interactions.
By equipping scientists with the means to explore and manipulate protein interactions, we are opening doors to novel therapeutic strategies that can address the challenges of previously undruggable targets. Explore our PPI Technologies.
RNA: A New Frontier in Precision Drug Targeting
Exploring RNA as a therapeutic target represents a frontier in the battle against the undruggable. This approach opens up a new realm of possibilities for modulating disease-causing genes previously inaccessible to traditional small molecules or biologics.
At Promega, we are pioneering the tools and techniques necessary to harness this potential, offering researchers the capabilities to study RNA with unprecedented precision and specificity. Discover how targeting RNA can revolutionize drug discovery and provide novel solutions for challenging targets. Explore our RNA Targeting Solutions.
